Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	KISS Igor BORTLÍČEK Zbyněk MELICHAR Bohuslav POPRACH Alexander HALÁMKOVÁ Jana VYZULA Rostislav DUŠEK Ladislav BUCHLER Tomas
Year of publication	2014
Type	Article in Periodical
Magazine / Source	Anticancer Research
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival
Description	The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.